Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Umeclidinium/Vilanterol Outperforms Rivals in Low-Risk COPD

Key clinical point: In low-risk patients with COPD who were not using inhaled corticosteroids, umeclidinium/vilanterol outperformed umeclidinium and salmeterol.

Major finding: Over 24 weeks, clinically important deterioration was less common in patients who took umeclidinium/vilanterol vs. umeclidinium (16%-25% improvement, P < .01) and salmeterol (26%-41% improvement, P < .001).

Study details: 24-week, double-blind, randomized, double-dummy, parallel-group trial of umeclidinium/vilanterol (62.5/25mcμg once-daily), umeclidinium (62.5 mcg once-daily) or salmeterol (50 mcg twice-daily).

Disclosures: GlaxoSmithKline funded the study. Multiple authors have relationships with the company such as grant support and current or former employment. Multiple authors have other various disclosures.

Citation:

Maltais F et al. Respir Res. 2019;20:238.